AbbVie Inc. closed 15.68% short of its 52-week high of $207.32, which the company achieved on October 31st.

AbbVie Inc. closed 14.67% below its 52-week high of $207.32, which the company achieved on October 31st.

We recently published a list of the 12 Best Stocks to Buy in 2025 for Beginners. In this article, we are going to take a look ...

AbbVie Inc (NYSE:ABBV)., a leading biopharmaceutical company with a market capitalization of $311.86 billion, has been at the forefront of the industry with its diverse portfolio of pharmaceuticals ...

DCF analysis, a reliable and data-driven approach to estimating its intrinsic value. Instead of using future free cash flow ...

AbbVie plans to release Q4 2024 results on Jan. 31. Analysts predict $14.8 billion in sales, $2.10 EPS. Immunology growth ...

AbbVie and Neomorph are set to enter a partnership and option-to-license agreement to develop molecular glue degraders.

AbbVie stock trades at a forward price-to-earnings (P/E) ratio of 14.2, representing a significant discount to the S&P 500's ...

We recently published a list of 11 Best Bear Market Stocks To Invest In Now. In this article, we are going to take a look at ...

We recently compiled a list of the 10 Best Halal Dividend Stocks To Invest In. In this article, we are going to take a look ...

Research analysts at William Blair decreased their FY2025 earnings per share (EPS) estimates for shares of AbbVie in a note ...

William Blair reduced their FY2024 EPS estimates for shares of AbbVie in a research note issued on Tuesday, January 21st.